Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Vascular safety of erenumab for migraine prevention.

Kudrow D, Pascual J, Winner PK, Dodick DW, Tepper SJ, Reuter U, Hong F, Klatt J, Zhang F, Cheng S, Picard H, Eisele O, Wang J, Latham JN, Mikol DD.

Neurology. 2019 Dec 18. pii: 10.1212/WNL.0000000000008743. doi: 10.1212/WNL.0000000000008743. [Epub ahead of print]

PMID:
31852816
2.

The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.

Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, Klatt J, Cheng S, Zhang F, Wen S, Ritter S, Lenz RA, Mikol DD.

Cephalalgia. 2020 Jan;40(1):28-38. doi: 10.1177/0333102419894559. Epub 2019 Dec 9.

PMID:
31816249
3.

Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.

Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, Xue F, Picard H, Zhang F, Wang A, Zhou Y, Hong F, Klatt J, Mikol DD.

Cephalalgia. 2019 Dec;39(14):1798-1808. doi: 10.1177/0333102419888222. Epub 2019 Nov 10.

PMID:
31707815
4.

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.

Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hirama T, Mikol DD.

Headache. 2019 Nov;59(10):1731-1742. doi: 10.1111/head.13652. Epub 2019 Oct 14.

5.

Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ).

Kawata AK, Hareendran A, Shaffer S, Mannix S, Thach A, Desai P, Mikol DD, Ortmeier B, Bayliss M, Buse DC.

Headache. 2019 Sep;59(8):1253-1269. doi: 10.1111/head.13569. Epub 2019 Jun 5.

6.
7.

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD.

Cephalalgia. 2019 Oct;39(11):1455-1464. doi: 10.1177/0333102419854082. Epub 2019 May 30.

8.

Correction to: A Multi‑Center, Open‑Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.

Xu Y, Gabriel K, Wang Y, Zhou Y, Eisele O, Vutikullird A, Mikol DD, Lee E.

CNS Drugs. 2019 May;33(5):523. doi: 10.1007/s40263-019-00638-y.

9.

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.

Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R.

Neurology. 2019 May 7;92(19):e2250-e2260. doi: 10.1212/WNL.0000000000007452. Epub 2019 Apr 17.

10.

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.

Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD.

Neurology. 2019 May 14;92(20):e2309-e2320. doi: 10.1212/WNL.0000000000007497. Epub 2019 Apr 17.

11.

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Lenz R, Mikol DD.

Cephalalgia. 2019 Jun;39(7):817-826. doi: 10.1177/0333102419835459. Epub 2019 Apr 13.

PMID:
30982348
12.

A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.

Xu Y, Gabriel K, Wang Y, Zhou Y, Eisele O, Vutikullird A, Mikol DD, Lee E.

CNS Drugs. 2019 May;33(5):513-522. doi: 10.1007/s40263-019-00626-2. Erratum in: CNS Drugs. 2019 May 6;:.

13.

Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes - The Migraine Functional Impact Questionnaire (MFIQ).

Hareendran A, Skalicky A, Mannix S, Lavoie S, Desai P, Bayliss M, Thach AV, Mikol DD, Buse DC.

Headache. 2018 Nov;58(10):1612-1628. doi: 10.1111/head.13420. Epub 2018 Oct 30.

14.

Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.

Yusuf A, Chia V, Xue F, Mikol DD, Bollinger L, Cangialose C.

Pharmacoepidemiol Drug Saf. 2018 Dec;27(12):1309-1315. doi: 10.1002/pds.4658. Epub 2018 Sep 21.

15.

Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.

Buse DC, Lipton RB, Hallström Y, Reuter U, Tepper SJ, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA.

Cephalalgia. 2018 Sep;38(10):1622-1631. doi: 10.1177/0333102418789072. Epub 2018 Aug 7.

PMID:
30086681
16.

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, Cheng S, Zhang F, Lenz R, Klatt J, Mikol DD.

Cephalalgia. 2018 Sep;38(10):1611-1621. doi: 10.1177/0333102418788347. Epub 2018 Jul 8.

PMID:
29984601
17.

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina.

Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, Mikol DD.

Headache. 2018 May;58(5):715-723. doi: 10.1111/head.13316.

18.

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.

Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA.

Cephalalgia. 2018 May;38(6):1026-1037. doi: 10.1177/0333102418759786. Epub 2018 Feb 22.

PMID:
29471679
19.

Preventive Therapies for Chronic Migraine.

Goadsby PJ, Picard H, Mikol DD.

N Engl J Med. 2018 Feb 22;378(8):774-5. doi: 10.1056/NEJMc1716990. No abstract available.

PMID:
29469553
20.

A Controlled Trial of Erenumab for Episodic Migraine.

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA.

N Engl J Med. 2017 Nov 30;377(22):2123-2132. doi: 10.1056/NEJMoa1705848.

21.

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.

Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA.

Neurology. 2017 Sep 19;89(12):1237-1243. doi: 10.1212/WNL.0000000000004391. Epub 2017 Aug 23.

PMID:
28835404
22.

Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.

Muralidharan KK, Kuesters G, Plavina T, Subramanyam M, Mikol DD, Gopal S, Nestorov I.

J Clin Pharmacol. 2017 Aug;57(8):1017-1030. doi: 10.1002/jcph.894. Epub 2017 Apr 11.

PMID:
28398628
23.

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J; ATAMS Study Group.

Lancet Neurol. 2014 Apr;13(4):353-63. doi: 10.1016/S1474-4422(14)70028-6. Epub 2014 Mar 6.

PMID:
24613349
24.

The changing face of multiple sclerosis clinical trial populations.

Uitdehaag BM, Barkhof F, Coyle PK, Gardner JD, Jeffery DR, Mikol DD.

Curr Med Res Opin. 2011 Aug;27(8):1529-37. doi: 10.1185/03007995.2011.591370. Epub 2011 Jun 15. Review.

PMID:
21671851
25.

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group.

Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11.

PMID:
18789766
26.

Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.

Freedman MS, Hughes B, Mikol DD, Bennett R, Cuffel B, Divan V, LaVallee N, Al-Sabbagh A.

Eur Neurol. 2008;60(1):1-11. doi: 10.1159/000127972. Epub 2008 Apr 25. Review.

27.

High-throughput profiling of ion channel activity in primary human lymphocytes.

Estes DJ, Memarsadeghi S, Lundy SK, Marti F, Mikol DD, Fox DA, Mayer M.

Anal Chem. 2008 May 15;80(10):3728-35. doi: 10.1021/ac800164v. Epub 2008 Apr 24.

PMID:
18433147
28.

Neuromyelitis optica in a mother and daughter.

Braley T, Mikol DD.

Arch Neurol. 2007 Aug;64(8):1189-92.

PMID:
17698711
29.

Serum IgE reactive against small myelin protein-derived peptides is increased in multiple sclerosis patients.

Mikol DD, Ditlow C, Usatin D, Biswas P, Kalbfleisch J, Milner A, Calenoff E.

J Neuroimmunol. 2006 Nov;180(1-2):40-9. Epub 2006 Sep 20.

PMID:
16996143
30.

Neurofibromin binds to caveolin-1 and regulates ras, FAK, and Akt.

Boyanapalli M, Lahoud OB, Messiaen L, Kim B, Anderle de Sylor MS, Duckett SJ, Somara S, Mikol DD.

Biochem Biophys Res Commun. 2006 Feb 24;340(4):1200-8. Epub 2006 Jan 4.

PMID:
16405917
31.

Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.

Bernitsas E, Wei W, Mikol DD.

Ann Neurol. 2006 Jan;59(1):206-9.

32.

Oligodendrocyte-myelin glycoprotein is present in lipid rafts and caveolin-1-enriched membranes.

Boyanapalli M, Kottis V, Lahoud O, Bamri-Ezzine S, Braun PE, Mikol DD.

Glia. 2005 Nov 15;52(3):219-27.

33.

Identifying and treating patients with suboptimal responses.

Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, Agius M, Bashir R, Collins TE, Herndon R, Kinkel P, Mikol DD, Picone MA, Rivera V, Tornatore C, Zwibel H.

Neurology. 2004 Dec 28;63(12 Suppl 6):S33-40. Review.

PMID:
15623669
34.

Mitoxantrone treatment of multiple sclerosis: safety considerations.

Cohen BA, Mikol DD.

Neurology. 2004 Dec 28;63(12 Suppl 6):S28-32. Review.

PMID:
15623667
35.

Cerebellitis in an adult with abnormal magnetic resonance imaging findings prior to the onset of ataxia.

Gruis KL, Moretti P, Gebarski SS, Mikol DD.

Arch Neurol. 2003 Jun;60(6):877-80.

PMID:
12810494
36.

Schwann cell caveolin-1 expression increases during myelination and decreases after axotomy.

Mikol DD, Scherer SS, Duckett SJ, Hong HL, Feldman EL.

Glia. 2002 May;38(3):191-9.

37.

Treat early, but treat hard: Interferon-beta dose makes a difference.

Mikol DD.

J Neuroophthalmol. 2001 Dec;21(4):237-9. No abstract available.

PMID:
11756850
38.

Neurophilins and the nervous system.

Mikol DD, Feldman EL.

Muscle Nerve. 1999 Oct;22(10):1337-40. Review. No abstract available.

39.

Caveolin-1 expression in Schwann cells.

Mikol DD, Hong HL, Cheng HL, Feldman EL.

Glia. 1999 Jul;27(1):39-52.

40.

Expression of the oligodendrocyte-myelin glycoprotein by neurons in the mouse central nervous system.

Habib AA, Marton LS, Allwardt B, Gulcher JR, Mikol DD, Högnason T, Chattopadhyay N, Stefansson K.

J Neurochem. 1998 Apr;70(4):1704-11.

41.

The oligodendrocyte-myelin glycoprotein of mouse: primary structure and gene structure.

Mikol DD, Rongnoparut P, Allwardt BA, Marton LS, Stefansson K.

Genomics. 1993 Sep;17(3):604-10.

PMID:
8244377
42.

Structure and chromosomal localization of the human gene for a brain form of prostaglandin D2 synthase.

White DM, Mikol DD, Espinosa R, Weimer B, Le Beau MM, Stefansson K.

J Biol Chem. 1992 Nov 15;267(32):23202-8.

43.

Structure and chromosomal localization of the gene for the oligodendrocyte-myelin glycoprotein.

Mikol DD, Alexakos MJ, Bayley CA, Lemons RS, Le Beau MM, Stefansson K.

J Cell Biol. 1990 Dec;111(6 Pt 1):2673-9.

44.
45.
47.

A peanut agglutinin binding glycoprotein in CNS myelin and oligodendrocytes.

Mikol DD, Szuchet S, Stefansson K.

Ann N Y Acad Sci. 1988;540:409-12.

PMID:
3207269

Supplemental Content

Loading ...
Support Center